Crossject: Syneos Health hired for Zepizure in the USA
As part of this agreement, Syneos Health will provide support for all pre-launch and product launch activities, bringing Crossject's U.S. presence and expertise in bringing new treatments to market.
In 2022, Crossject has been awarded a contract with BARDA, for the advanced regulatory development and supply of Zepizure to the U.S. Strategic National Stockpile (SNS), upon FDA approval.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction